肝硬化诊治指南

doi:10.3969/j.issn.1672-5069.2019.06.004

[1] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology. 2018. 69: 406-460.
[2] European Association for the Study of the Live. EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis[J].J Hepatol,2010,53(3):397-417.DOI:10. 1016/j. jhep. 2010. 05. 004.
[3] Runyon BA;AASLD.Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012[J]. Hepatology,2013,57(4):1651-1653,DOI:10.1002/hep.26359.
[4] Pellicoro A, Ramachandran P, John P.Iredale & Jonathan A. Fallowfield. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nature Reviews Immunology.2014;14:181-194.
[5] Ning Yang, Juan-Juan Shi, Feng-Ping Wu, Mei Li, Xin Zhang, Ya-Ping Li, Song Zhai, Xiao-Li Jia, Shuang-Suo Dang.Caffeic acid phenethyl ester up-regulates antioxidant levels in hepatic stellate cell line T6 via an Nrf2-mediated mitogen activated protein kinases pathway. World [J] Gastroenterol. 2017 ; 23(7): 1203-1214.
[6] Xu X., Duan Z., Ding H.et al.Chinese guidelines on the management of ascites and its related complications in cirrhosis. Hepatol Int. 2019, 13(1): 1-21.
[7] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南. 中华内科杂志,2016;55(1):57-72.
[8] 中华医学会肝病学分会.肝硬化肝性脑病诊疗指南.中华内科杂志. 2018;;57(10). 705-718.
[9] Berzigotti, A. and Abraldes, J. G.Impact of obesity and insulin-resistance on cirrhosis and portal hypertension. Gastroenterol Hepatol. 2013, 36(8): 527-533.
[10] Berzigotti A., Albillos A., Villanueva C.et al.Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. Hepatology. 2017, 65(4): 1293-1305.
[11] Parker R., Kim S. J., Im G. Y.et al.Obesity in acute alcoholic hepatitis increases morbidity and mortality. EBioMedicine. 2019, 45: 511-518.
[12] Montano-Loza, A. J., Angulo, P., Meza-Junco, J. et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. [J] Cachexia Sarcopenia Muscle. 2016, 7(2): 126-135.
[13] Hara N., Iwasa M., Sugimoto R.et al.Sarcopenia and Sarcopenic Obesity Are Prognostic Factors for Overall Survival in Patients with Cirrhosis. Intern Med. 2016, 55(8): 863-870.
[14] Abbas, M. and Abbas, Z.Serum cholinesterase: A predictive biomarker of hepatic reserves in chronic hepatitis D. World [J] Hepatol. 2017, 9(22): 967-972.
[15] Dufour D. R., Lott J. A., Nolte F. S.et al.Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem. 2000, 46(12): 2050-2068.
[16] Anthony P. P., Ishak K. G., Nayak N. C.et al.The morphology of cirrhosis: definition, nomenclature, and classification. Bull World Health Organ. 1977, 55(4): 521-540.
[17] Malinchoc M., Kamath P. S., Gordon F. D.et al.A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000, 31(4): 864-871.
[18] Wu S. L., Zheng Y. X., Tian Z. W.et al.Scoring systems for prediction of mortality in decompensated liver cirrhosis: A meta-analysis of test accuracy. World [J] Clin Cases. 2018, 6(15): 995-1006.
[19] Majlesara A., Golriz M., Hafezi M.et al.Indocyanine green fluorescence imaging in hepatobiliary surgery. Photodiagnosis Photodyn Ther. 2017, 17: 208-215.
[20] 中华医学会肝病学分会原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015). 中华肝脏病杂志. 2016, 1(24).
[21] 中华医学会肝病学分会药物性肝病学组药物性肝损伤诊治指南. 中华肝脏病杂志. 2015, 11(23).
[22] 中国肝炎防治基金会瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版). 中华肝脏病杂志. 2019, 3(27).
[23] He Y. B., Bai L., Jiang Y.et al.Application of a Three-Dimensional Reconstruction Technique in Liver Autotransplantation for End-Stage Hepatic Alveolar Echinococcosis. [J] Gastrointest Surg. 2015, 19(8): 1457-1465.
[24] Cai W., Fan Y., Hu H.et al.Postoperative liver volume was accurately predicted by a medical image three dimensional visualization system in hepatectomy for liver cancer. Surg Oncol. 2017, 26(2): 188-194.
[25] Lo, R. C. and Kim, H.Histopathological evaluation of liver fibrosis and cirrhosis regression. Clin Mol Hepatol. 2017, 23(4): 302-307.
[26] Kim S. U., Oh H. J., Wanless I. R.et al.The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis. [J] Hepatol. 2012, 57(3): 556-563.
[27] Deniz K., Ozcan S., Ozbakir O.et al.Regression of steatohepatitis-related cirrhosis. Semin Liver Dis. 2015, 35(2): 199-202.
[28] Bedossa, P. and Poynard, T.An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996, 24(2): 289-293.
[29] Nagula S., Jain D., Groszmann R. J.et al.Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. [J] Hepatol. 2006, 44(1): 111-117.
[30] Kumar M., Sakhuja P., Kumar A.et al.Histological subclassification of cirrhosis based on histological-haemodynamic correlation. Aliment Pharmacol Ther. 2008, 27(9): 771-779.
[31] 中国门静脉高压诊断与监测研究组(CHESS) 中国肝静脉压力梯度临床应用专家共识(2018版). 中华肝脏病杂志. 2018, 11(26).
[32] Qi X., An W., Liu F.et al.Virtual Hepatic Venous Pressure Gradient with CT Angiography (CHESS 1601): A Prospective Multicenter Study for the Noninvasive Diagnosis of Portal Hypertension. Radiology. 2019, 290(2): 370-377.
[33] Liu F., Ning Z., Liu Y.et al.Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study. EBioMedicine. 2018, 36: 151-158.
[34] Morgan M. Y., Madden A. M., Soulsby C. T.et al.Derivation and validation of a new global method for assessing nutritional status in patients with cirrhosis. Hepatology. 2006, 44(4): 823-835.
[35] 中华医学会肝病学分会终末期肝病临床营养指南. 中华肝脏病杂志. 2019, 5(27).
[36] WHO Guidelines Approved by the Guidelines Review Committee. in Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection (World Health Organization Copyright (c) World Health Organization2015., Geneva: 2015).Issue.
[37] Buti M., Fung S., Gane E.et al.Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int. 2015, 9(2): 243-250.
[38] Kong Y., Sun Y., Zhou J.et al.Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. [J] Viral Hepat. 2019, 26(5): 576-585.
[39] Russo F. P., Zanetto A., Campello E.et al.Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. Liver Int. 2018, 38(12): 2210-2218.
[40] Grgurevic, I., Bozin, T. and Madir, A.Hepatitis C is now curable, but what happens with cirrhosis and portal hypertension afterwards? Clin Exp Hepatol. 2017, 3(4): 181-186.
[41] Marcellin, P. and Asselah, T.Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal. [J] Gastroenterol Hepatol. 2013, 28(6): 912-923.
[42] Arvaniti V., D'Amico G., Fede G.et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology.2010, 139(4): 1246-1256, 1256.e1241-1245.
[43] Sultan S., Pauwels A., Poupon R.et al.[Chylous ascites in cirrhosis. Retrospective study of 20 cases]. Gastroenterol Clin Biol. 1990, 14(11): 842-847.
[44] Rector W. G.,Jr. Spontaneous chylous ascites of cirrhosis. [J] Clin Gastroenterol. 1984, 6(4): 369-372.
[45] Steinemann D. C., Dindo D., Clavien P. A.et al. Atraumatic chylous ascites: systematic review on symptoms and causes. J Am Coll Surg.2011, 212(5): 899-905.e891-894.
[46] Badillo, R. and Rockey, D. C.Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature. Medicine (Baltimore). 2014, 93(3): 135-142.
[47] Garbuzenko, D. V. and Arefyev, N. O.Hepatic hydrothorax: An update and review of the literature. World [J] Hepatol. 2017, 9(31): 1197-1204.
[48] Reiberger T., Puspok A., Schoder M.et al.Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr. 2017, 129(Suppl 3): 135-158.
[49] Smith E., Tekola B., Patrie J.et al. Clinical Characterization of Gastric Antral Vascular Ectasia: A Potential Manifestation of the Metabolic Syndrome. Am J Med.2016, 129(12): 1329.e1319-1329.e1323.
[50] Tsai C. J., Sanaka M. R., Menon K. V.et al.Balloon-assisted enteroscopy in portal hypertensive enteropathy. Hepatogastroenterology. 2014, 61(134): 1635-1641.
[51] De Palma, G. D., Rega, M., Masone, S. et al. Mucosal abnormalities of the small bowel in patients with cirrhosis and portal hypertension: a capsule endoscopy study. Gastrointest Endosc. 2005, 62(4): 529-534.
[52] Besa C., Cruz J. P., Huete A.et al.Portal biliopathy:a multitechnique imaging approach. Abdom Imaging. 2012, 37(1): 83-90.
[53] Nardone R., Holler Y., Storti M.et al.Spinal cord involvement in patients with cirrhosis. World [J] Gastroenterol. 2014, 20(10): 2578-2585.
[54] Renjen P. N., Khanna L., Rastogi R.et al.Acquired hepatocerebral degeneration. BMJ Case Rep. 2013, 2013.
[55] Burkhard P. R., Delavelle J., Du Pasquier, R. et al. Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. Arch Neurol. 2003, 60(4): 521-528.
[56] Lewis M. B.,MacQuillan, G., Bamford, J. M. et al. Delayed myelopathic presentation of the acquired hepatocerebral degeneration syndrome. Neurology. 2000, 54(4): 1011.
[57] Burgos A., Bermejo P. E., Calleja J. L.et al.Acquired chronic hepatocerebral degeneration due to cirrhosis from non-alcoholic steatohepatitis. Rev Esp Enferm Dig. 2009, 101(11): 806-811.
[58] Angeli P.,Garcia-Tsao, G., Nadim, M. K. et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019.
[59] Rosi S., Piano S., Frigo A. C.et al.New ICA criteria for the diagnosis of acute kidney injury in cirrhotic patients: can we use an imputed value of serum creatinine? Liver Int. 2015, 35(9): 2108-2114.
[60] Shah N., Dhar D., El Zahraa Mohammed, F. et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression. [J] Hepatol. 2012, 56(5): 1047-1053.
[61] Adebayo D., Morabito V., Davenport A.et al.Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int. 2015, 87(3): 509-515.
[62] Bucsics, T. and Krones, E.Renal dysfunction in cirrhosis:acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf). 2017, 5(2): 127-137.
[63] Wong F.,O'Leary, J. G., Reddy, K. R. et al. Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes. Am [J] Gastroenterol. 2017, 112(7): 1103-1110.
[64] Angeli P., Gines P., Wong F.et al.Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. [J] Hepatol. 2015, 62(4): 968-974.
[65] Patidar K. R., Kang L., Bajaj J. S.et al.Fractional excretion of urea: A simple tool for the differential diagnosis of acute kidney injury in cirrhosis. Hepatology. 2018, 68(1): 224-233.
[66] 王文娟肝硬化患者急性肾损伤的临床特点及危险因素分析. 中华内科杂志. 2018, 12(57).
[67] Wehmeyer M. H., Heuer A. J., Benten D.et al.High Rate of Cardiac Abnormalities in a Postmortem Analysis of Patients Suffering From Liver Cirrhosis. [J] Clin Gastroenterol. 2015, 49(10): 866-872.
[68] Moller S., Hove J. D., Dixen U.et al.New insights into cirrhotic cardiomyopathy. Int [J] Cardiol. 2013, 167(4): 1101-1108.
[69] Mehta G., Gustot T., Mookerjee R. P.et al.Inflammation and portal hypertension - the undiscovered country. [J] Hepatol. 2014, 61(1): 155-163.
[70] Nagueh S. F., Smiseth O. A., Appleton C. P.et al.Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart [J] Cardiovasc Imaging. 2016, 17(12): 1321-1360.
[71] Kwon, H. M. and Hwang, G. S.Cardiovascular dysfunction and liver transplantation. Korean [J] Anesthesiol. 2018, 71(2): 85-91.
[72] Zhao J., Qi X., Hou F.et al.Prevalence, Risk Factors and In-hospital Outcomes of QTc Interval Prolongation in Liver Cirrhosis. Am [J] Med Sci. 2016, 352(3): 285-295.
[73] Vannucci A., Rathor R., Vachharajani N.et al.Atrial fibrillation in patients undergoing liver transplantation-a single-center experience. Transplant Proc. 2014, 46(5): 1432-1437.
[74] Krowka M. J., Fallon M. B., Kawut S. M.et al.International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation. 2016, 100(7): 1440-1452.
[75] Sarin S. K., Philips C. A., Kamath P. S.et al. Toward a Comprehensive New Classification of Portal Vein Thrombosis in Patients With Cirrhosis. Gastroenterology.2016, 151(4): 574-577.e573.
[76] EASL Clinical Practice Guidelines: Vascular diseases of the liver. [J] Hepatol. 2016, 64(1): 179-202.
[77] de Franchis, R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. [J] Hepatol. 2015, 63(3): 743-752.
[78] Basili S., Pastori D., Raparelli V.et al.Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician. Therap Adv Gastroenterol. 2018, 11: 1756284818793561.
[79] Englesbe M. J., Schaubel D. E., Cai S.et al.Portal vein thrombosis and liver transplant survival benefit. Liver Transpl. 2010, 16(8): 999-1005.
[80] Chen H., Turon F., Hernandez-Gea, V. et al. Nontumoral portal vein thrombosis in patients awaiting liver transplantation. Liver Transpl. 2016, 22(3): 352-365.
[81] Haris, M. and Thachil, J.Portal vein thrombosis - a primer for the general physician. Clin Med (Lond). 2017, 17(3): 212-219.
[82] Dupuis M., Spahr L., Giostra E.et al.[Portal vein thrombosis in patients with cirrhosis]. Rev Med Suisse. 2017, 13(572): 1470-1473.
[83] von Kockritz L., De Gottardi A., Trebicka J.et al. Portal vein thrombosis in patients with cirrhosis. Gastroenterol Rep (Oxf). 2017, 5(2): 148-156.
[84] To, U. K. and Garcia-Tsao, G. PRO: Patients With Advanced Cirrhosis and Portal Vein Thrombosis Should Receive Anticoagulation. Clin Liver Dis (Hoboken). 2018, 12(3): 74-79.
[85] Zhou J., Sun H. C., Wang Z.et al.Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer. 2018, 7(3): 235-260.
[86] Gonzalez-Calvin, J. L., Gallego-Rojo, F., Fernandez-Perez, R. et al. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. [J] Clin Endocrinol Metab. 2004, 89(9): 4325-4330.
[87] Goubraim R., Kabbaj N., Salihoun M.et al.Metabolic Bone Disease in Viral Cirrhosis: A Prospective Study. ISRN Hepatol. 2013, 2013: 276563.
[88] Raszeja-Wyszomirska, J. and Miazgowski, T. Osteoporosis in primary biliary cirrhosis of the liver. Prz Gastroenterol. 2014, 9(2): 82-87.
[89] Engelke K., Libanati C., Liu Y.et al.Quantitative computed tomography (QCT) of the forearm using general purpose spiral whole-body CT scanners: accuracy, precision and comparison with dual-energy X-ray absorptiometry (DXA). Bone. 2009, 45(1): 110-118.
[90] Kim G., Kang S. H., Kim M. Y.et al.Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis. PLoS One. 2017, 12(10): e0186990.
[91] Giusto M., Lattanzi B., Albanese C.et al.Sarcopenia in liver cirrhosis: the role of computed tomography scan for the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry. Eur [J] Gastroenterol Hepatol. 2015, 27(3): 328-334.
[92] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2019更新版).中华肝脏病杂志. 2019,待发表.
[93] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019更新版).中华肝脏病杂志. 2019,待发表.
[94] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018更新版). 中华肝脏病杂志 2018;26:188-194.
[95] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志 2018;21(2):177-186.
[96] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015). 临床肝胆病杂志. 2016:9-22.
[97] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会. 原发性硬化性胆管炎诊断和治疗专家共识(2015). 中华肝脏病杂志. 2016:14-22.
[98] Kamisawa T, Nakazawa T, Tazuma S, Zen Y, Tanaka A, Ohara H, Muraki T, et al.Clinical practice guidelines for IgG4-related sclerosing cholangitis. J Hepatobiliary Pancreat Sci 2019;26:9-42.
[99] European Association for Study of L. EASL Clinical Practice Guidelines: Wilson's disease. [J] Hepatol. 2012;56:671-685.
[100] Roberts EA, Schilsky ML, American Association for Study of Liver D. Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47:2089-2111.
[101] Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet. 2016;388:706-716.
[102] 黄昂, 梁庆升, 孙颖, 邹正升.慢性药物性肝损伤的诊治研究进展. 传染病信息. 2018:105-107.
[103] Colley DG, Bustinduy AL, Secor WE, King CH.Human schistosomiasis. Lancet. 2014;383:2253-2264.
[104] Qian MB, Utzinger J, Keiser J, Zhou XN. Clonorchiasis. Lancet. 2016;387:800-810.
[105] 中华医学会感染病学分会, 肝脏炎症及其防治专家共识专家委员会. 肝脏炎症及其防治专家共识. 中华肝脏病杂志. 2014:94-103.
[106] Zhang L, Schuppan D. Traditional Chinese Medicine (TCM) for fibrotic liver disease: hope and hype. [J] Hepatol. 2014;61:166-168.
[107] 南月敏, 孔令波.肝硬化的中西医结合诊治进展. 中华肝脏病杂志. 2018:328-331.
[108] 田玉岭, 朱晓云, 殷卫卫, 藏志栋, 王雷, 傅熙玲.扶正化瘀胶囊序贯联合核苷(酸)类似物对慢性乙型肝炎肝纤维化指标的影响. 中华肝脏病杂志. 2013;21:514-518.
[109] 蒋永芳, 马静, 贺波, 李耐萍, 唐伟, 龚国忠.阿德福韦酯联合安络化纤丸治疗慢性乙型肝炎的疗效. 中华肝脏病杂志. 2012;20:344-347.
[110] 杨年欢, 袁国盛, 周宇辰, et al.恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化96周的临床疗效. 南方医科大学学报. 2016:775-779.
[111] 肖定洪, 顾杰, 蔡虹, et al.扶正化瘀胶囊预防肝硬化患者食管静脉曲张破裂出血的随机对照多中心临床研究. 中华肝脏病杂志. 2014:594-599.
[112] 王林、卢玮、高玉华、曹曦、裴斐、刘学恩、庄辉. 安络化纤丸对肝纤维化大鼠组织基质金属蛋白酶及其抑制物表达的影响. 中华肝脏病杂志. 2019;27(4):267-273.
[113] Lizaola B, Bonder A, Trivedi HD, Tapper EB, Cardenas A.Review article: the diagnostic approach and current management of chylous ascites. Aliment Pharmacol Ther. 2017;46:816-824.
[114] Bhardwaj R, Vaziri H, Gautam A, Ballesteros E, Karimeddini D, Wu GY.Chylous Ascites: A Review of Pathogenesis, Diagnosis and Treatment. [J] Clin Transl Hepatol. 2018;6:105-113.
[115] 李越, 丁惠国. 乳糜性腹水诊治现状. 实用肝脏病杂志. 2018:21(5)665-668.
[116] Berzigotti A, Magalotti D, Cocci C, Angeloni L, Pironi L, Zoli M.Octreotide in the outpatient therapy of cirrhotic chylous ascites: a case report. Dig Liver Dis. 2006;38:138-142.
[117] Zhou DX, Zhou HB, Wang Q, Zou SS, Wang H, Hu HP.The effectiveness of the treatment of octreotide on chylous ascites after liver cirrhosis. Dig Dis Sci. 2009;54:1783-1788.
[118] 刘揆亮, 孙宇光, 夏松, 沈文彬, 吴静, 林香春.肝硬化合并乳糜性腹水34例临床特点分析. 中华消化杂志. 2014:96-99.
[119] 胡丽娟, 王丽晶, 简易成, 熊伍军.奥曲肽治愈肝硬化乳糜性腹水1例并文献复习. 临床肝胆病杂志. 2012:624-625.
[120] Leong RW, House AK, Jeffrey GP.Chylous ascites caused by portal vein thrombosis treated with octreotide. [J] Gastroenterol Hepatol. 2003;18:1211-1213.
[121] Tsauo J, Shin JH, Han K, et al.Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Chylothorax and Chylous Ascites in Cirrhosis: A Case Report and Systematic Review of the Literature. [J] Vasc Interv Radiol. 2016;27:112-116.
[122] Urrunaga NH, Singal AG, Cuthbert JA, Rockey DC.Hemorrhagic ascites. Clinical presentation and outcomes in patients with cirrhosis. [J] Hepatol. 2013;58:1113-1118.
[123] Pache I, Bilodeau M.Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther. 2005;21:525-529.
[124] Pereira SP, Rowbotham D, Fitt S, Shearer MJ, Wendon J, Williams R.Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. J Hepatol. 2005;42:365-370.
[125] Lee EW, Shahrouki P, Alanis L, Ding P, Kee ST.Management Options for Gastric Variceal Hemorrhage. JAMA Surg 2019;154:540-548.
[126] Hosking SW, Kennedy HJ, Seddon I, Triger DR.The role of propranolol in congestive gastropathy of portal hypertension. Hepatology. 1987;7:437-441.
[127] Perez-Ayuso RM, Pique JM, Bosch J, et al.Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet. 1991;337:1431-1434.
[128] Zhou Y, Qiao L, Wu J, Hu H, Xu C.Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: a controlled study. [J] Gastroenterol Hepatol. 2002;17:973-979.
[129] Patwardhan VR, Cardenas A.Review article: the management of portal hypertensive gastropathy and gastric antral vascular ectasia in cirrhosis. Aliment Pharmacol Ther. 2014;40:354-362.
[130] Kamath PS, Lacerda M, Ahlquist DA, McKusick MA, Andrews JC, Nagorney DA. Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology. 2000;118:905-911.
[131] Urrunaga NH, Rockey DC.Portal hypertensive gastropathy and colopathy. Clin Liver Dis. 2014;18:389-406.
[132] 中华医学会感染病学分会. 终末期肝病合并感染诊治专家共识. 中华肝脏病杂志. 2018;26:568-578.
[133] Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, et al.Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 2017;45:486-552.
[134] Dhiman RK, Thumburu KK, Verma N, Chopra M, Rathi S, Dutta U, Singal AK, et al.Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review & Network Meta-analysis. Clin Gastroenterol Hepatol 2019.
[135] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版). 国际流行病学传染病学杂志. 2018;45:379-387.
[136] Wang H, Liu A, Bo W, Feng X, Hu Y.Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e0431.
[137] 占国清, 李芳, 李儒贵, et al.特利加压素治疗肝硬化顽固性腹水合并Ⅱ型肝肾综合征的疗效观察. 临床肝胆病杂志. 2015:1287-1290.
[138] Boyer TD, Sanyal AJ, Wong F, et al.Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. Gastroenterology. 2016;150:1579-1589 e1572.
[139] Israelsen M, Krag A, Allegretti AS, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev.2017;9:CD011532.
[140] Cavallin M, Kamath PS, Merli M, et al.Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015;62:567-574.
[141] 唐文, 蒋明德, 徐辉, 秦建平, 沈才飞.血浆置换联合去甲肾上腺素治疗重型肝炎合并Ⅱ型肝肾综合征的临床疗效分析. 北京医学. 2011:713-716.
[142] 董庆华, 郭利民, 刘景院, 焦以庆, 王宇, 熊号峰.白蛋白透析联合去甲肾上腺素治疗重型肝炎Ⅰ型肝肾综合征临床研究. 胃肠病学和肝病学杂志. 2009:852-854.
[143] Rossle M, Gerbes AL.TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 2010;59:988-1000.
[144] Lee YB, Lee JH.Cirrhotic cardiomyopathy: An independent prognostic factor for cirrhotic patients. Clin Mol Hepatol. 2018;24:372-373.
[145] Liu H, Jayakumar S, Traboulsi M, Lee SS.Cirrhotic cardiomyopathy: Implications for liver transplantation. Liver Transpl. 2017;23:826-835.
[146] Soulaidopoulos S, Cholongitas E, Giannakoulas G, Vlachou M, Goulis I.Review article: Update on current and emergent data on hepatopulmonary syndrome. World [J] Gastroenterol. 2018;24:1285-1298.
[147] Iqbal S, Smith KA, Khungar V.Hepatopulmonary Syndrome and Portopulmonary Hypertension: Implications for Liver Transplantation. Clin Chest Med. 2017;38:785-795.
[148] Fukushima KY, Yatsuhashi H, Kinoshita A, et al.Two cases of hepatopulmonary syndrome with improved liver function following long-term oxygen therapy. [J] Gastroenterol. 2007;42:176-180.
[149] Loffredo L, Pastori D, Farcomeni A, Violi F.Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. Gastroenterology 2017;153:480-487 e481.
[150] Cui SB, Shu RH, Yan SP, Wu H, Chen Y, Wang L, Zhu Q.Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B. Eur J Gastroenterol Hepatol 2015;27:914-919.
[151] Priyanka P, Kupec JT, Krafft M, Shah NA, Reynolds GJ.Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis. Int J Hepatol 2018;2018:8432781.
[152] 席娟, 刘熙钰, 陈嘉屿. 肝硬化并发门静脉血栓的抗凝治疗研究进展. 医学综述 2019;25:335-340.
[153] Koconis KG, Singh H, Soares G.Partial splenic embolization in the treatment of patients with portal hypertension: a review of the english language literature. J Vasc Interv Radiol 2007;18:463-481.
[154] 李学强, 王运兵, 龚建平, 王春. 部分脾动脉栓塞治疗肝硬化继发脾功能亢进的Meta分析. 中国介入影像与治疗学 2018;15:160-166.
[155] Bone HG, Hosking D, Devogelaer JP, et al.Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl [J] Med. 2004;350:1189-1199.
[156] Black DM, Reid IR, Boonen S, et al.The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:243-254.
[157] Zein CO, Jorgensen RA, Clarke B, et al.Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology. 2005;42:762-771.
[158] Guanabens N, Monegal A, Cerda D, et al.Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology. 2013;58:2070-2078.
[159] 巫香球. 心理护理干预对肝硬化患者遵医行为和生存质量的影响. 中国实用护理杂志 2011;27:3-4.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments